<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Zhu J</submitter><pubmed_abstract>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently poses a threat to human health. 3C-like proteinase (3CLpro) plays an important role in the viral life cycle. Hence, it is considered an attractive antiviral target protein. Whole-genome sequencing showed that the sequence homology between SARS-CoV-2 3CLpro and SARS-CoV 3CLpro is 96.08%, with high similarity in the substrate-binding region. Thus, assessing peptidomimetic inhibitors of SARS-CoV 3CLpro could accelerate the development of peptidomimetic inhibitors for SARS-CoV-2 3CLpro. Accordingly, we herein discuss progress on SARS-CoV-2 3CLpro peptidomimetic inhibitors. Inflammation plays a major role in the pathophysiological process of COVID-19. Small-molecule compounds tar</pubmed_abstract><journal>Drug design, development and therapy</journal><pagination>1067-1082</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9015912</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.</pubmed_title><pmcid>PMC9015912</pmcid><pubmed_authors>Lu L</pubmed_authors><pubmed_authors>Lin Q</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Chen K</pubmed_authors><pubmed_authors>Lyu J</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Chen H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.</name><description>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently poses a threat to human health. 3C-like proteinase (3CLpro) plays an important role in the viral life cycle. Hence, it is considered an attractive antiviral target protein. Whole-genome sequencing showed that the sequence homology between SARS-CoV-2 3CLpro and SARS-CoV 3CLpro is 96.08%, with high similarity in the substrate-binding region. Thus, assessing peptidomimetic inhibitors of SARS-CoV 3CLpro could accelerate the development of peptidomimetic inhibitors for SARS-CoV-2 3CLpro. Accordingly, we herein discuss progress on SARS-CoV-2 3CLpro peptidomimetic inhibitors. Inflammation plays a major role in the pathophysiological process of COVID-19. Small-molecule compounds tar</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-20T00:18:49.495Z</modification><creation>2025-02-19T01:53:37.343Z</creation></dates><accession>S-EPMC9015912</accession><cross_references><pubmed>35450403</pubmed><doi>10.2147/DDDT.S359009</doi></cross_references></HashMap>